ETAMI-Study: Early Thienopyridine treatment to improve primary PCI in Patients with Acute Myocardial Infarction - ETAMI

Stiftung Institut für Herzinfarktforschung0 个研究点目标入组 70 人开始时间: 2010年11月25日最近更新: 2014年2月3日

试验速览

暂无简介。

•Age >= 18years and < 75years
•Acute STEMI <= 12hrs.
•Planned percutaneous coronary intervention
•Legal capacity (including ability to understand the nature, scope, and possible consequences of the study participation)
•Informed consent
•First medical contact in prehospital setting, in a non-PCI hospital, or in a PCI-hospital, if the expected time until the start of the scheduled PCI is at least 20 minutes
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 70
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 70

•Age >= 75years
•Body weight < 60kg
•Thrombolytic therapy within 24hrs before randomization
•Oral anticoagulation
•Known hemorrhagic diathesis
•History of stroke or TIA
•Cardiogenic shock
•Evidence of active gastrointestinal or urogenital bleeding
•Major surgery within 6 weeks
•Contraindication to prasugrel or clopidogrel
•Severe renal or hepatic insufficiency
•Contraindication to coronary angiography
•Planned administration of GP IIb/IIIa inhibitor before angiography
•Pregnant or nursing women
•Patients currently treated with clopidogrel, prasugrel, ticlopidine, or ticagrelor
•Uncontrollable hypertension (blood pressure = 200/110 mmHg in repeated measurements)
•Treatment with NSAIDs
•Participation in another clinical or device trial within previous 30 days
•Expected time between administration of loading dose and start of PCI is < 20 minutes

发起方

Stiftung Institut für Herzinfarktforschung